Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data

Basit Öğe Kaydı
dc.contributor.authorDarçın, Tahir
dc.contributor.authorSerin, İstemi
dc.contributor.authorUğur, Mehmet Can
dc.contributor.authorEkinci, Ömer
dc.contributor.authorHindilerden, İpek Yönal
dc.contributor.authorAkpınar, Seval
dc.contributor.authorHacıbekiroğlu, Tuba
dc.date.accessioned2024-10-29T17:55:12Z
dc.date.available2024-10-29T17:55:12Z
dc.date.issued2024
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractObjective: We present data of patients with relapsed/ refractory T cell lymphomas treated with brentuximab vedotin (BV) in real-world practice. Material and Method: This study is an observational, multi-center, retrospective study. The data of patients (n=17) treated with BV alone from January 2014 until July 2020 in thirteen centers from Turkey were collected. Results: Bv was given as salvage chemotherapy to 17 patients with median age of 53. Nine (52.9%) patients had diagnosis of peripheral T cell lymphoma, not otherwise specified; 8 (47.1%) patients had anaplastic large T cell lymphoma. The median follow-up of the cohort was 20 months. Nine (52.9%) patients had complete response, 5 (29.5%) had partial response, 3 (17.6%) had progressive disease. The safety results aligned with the established profile of BV, included 2 pneumonia and 1 thrombocytopenia with grade 4. The median progression free survival of the cohort was 10 months. BV cycle and response to BV therapy were found to have an effect on the univariate analysis. Conclusion: In patients with relapsed/ refractory T cell lymphomas, BV seems to have convincing antitumor activity with favorable safety profile.
dc.identifier.doi10.52827/hititmedj.1320606
dc.identifier.endpage192
dc.identifier.issn2687-4717
dc.identifier.issue2en_US
dc.identifier.startpage186
dc.identifier.trdizinid1247726
dc.identifier.urihttps://doi.org/10.52827/hititmedj.1320606
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1247726
dc.identifier.urihttps://hdl.handle.net/20.500.11776/13885
dc.identifier.volume6
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofHitit medical journal (Online)
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectRelapse
dc.subjectbrentuximab vedotin
dc.subjectT cell lymphoma
dc.titleBrentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data
dc.typeArticle

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu